Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Massive??????🤣😂🤣😂🤣😂🤣Dump???????🤣😂🤣😂🤣😂 laughable
****BREAKING NEWS****MASSIVE 330K SHARE LOT DUMPED AT THE BID*****
So many posts of metric tonnage. Wasn’t Kim’s goal of3/4ton produced would have. Been
The starting point of sales an
D samples being sent out. Goal post moved again. Go figure
Patrik
Anyone else read the "Good Ruck" in scooby doo voice.
Excellent post, Mojo! Great job of exposing one of the greatest LIARS of all time. GO KBLB!
I just heard on National News that Vietnam wants an even low or no tariff. That will be resolved very soon I would think. I'm sure the never success boys and girls will protest!
"The fact that he didn't purchase those shares shows that he has absolutely no confidence in the company at all."
what an incredibly dumb remark...LMAO!...
Rice exercised warrants to the tune of 2.2 mil shares and sold only 24k shares to pay for them...he sold nothing more...but that shows a lack of confidence??...
and that is what you were referring to as Rice dumping shares?...
geez...the bashing is getting weaker and weaker...
you claimed that Rice was dumping shares....that is an outright lie...a pitiful bullshit lie...
Trade is what I like to talk about!
The country with the highest weighted average tariff rate globally is the Solomon Islands, with a rate of 20.7%. Vietnam has bilateral free trade agreements with SEVERAL countries. Therefore, Vietnam has several options in a "worse case scenario" as far as trade.
6man, first of all you posted a couple months ago that you were sick of the B.S and getting out. I guess you changed your mind. But to answer your question. Isn't kind of worrisome that you have no idea how the tariffs will affect it ? It's a legitimate concern I would think. Plus 100 other unanswered questions about KBLB. I'm not involved in the stock anymore but when I see you post something absurd, and only you alone because you are certainly brave behind a screen. I have to respond sometimes to your rediculous comments. Chin up fella. 👍
I cant wait to start worrying about tariffs on the many tons of product we will be producing…
Breaking News
Webslinger now believes kbl will be exporting multi ton quantities of spidersilk from Vietnam to America.
LMAO
If we sell products in S/E Asia or anywhere in the world, explain how those tariffs will affect Kblb…
Lol
Lmao…. Your posts get more ridiculous everyday. You have NO idea how any of the new tariff's will affect the company.
That is old news and was announced a week ago.
Unfortunately, it didn't work.
Trump slammed Vietnam with the 3rd highest reciprocal tariff.
Scope of Impact: Vietnam’s goods exports to the U.S. were worth more than $142 billion in the previous year, accounting for about 30% of Vietnam’s GDP. The 46% tariff could affect virtually all of these exports, potentially disrupting Vietnam’s economy, which has heavily relied on the U.S. as its top export market.
Rationale: The U.S. justification for the tariff centers on Vietnam’s large trade surplus with the U.S., which stood at $123.5 billion, one of the largest among U.S. trading partners. Additionally, the Trump administration has pointed to Vietnam’s alleged currency manipulation practices and non-tariff barriers as reasons for the reciprocal tariffs. The U.S. has historically used average duties as a benchmark for determining reciprocal tariffs, and Vietnam’s effective bilateral tariff rates, while lower in some calculations, have been a point of contention.
********** BREAKING NEWS*************Vietnam Cuts Tariffs on U.S. Energy and Agricultural Exports*********
LMAO… Seems fair to me…. You need to find some new material…
*****BREAKING NEWS*****TRUMP INSTITUTES NEW VIETNAM TARIFFS*****
Vietnam: 90% tariffs and other trade barriers on U.S. goods; 46% reciprocal tariffs.
Vietnam will receive the 3rd HIGHEST reciprocal tariff.
<< you are wrong >>
Show me the evidence.... You won't be able to, because you know it is BS.
I showed evidence that Rice dumped shares (since he did a cashless exercise, which by definition means that he dumped some of the shares to pay for the rest of the shares).
He could have actually bought all of the shares outright. At the bargain basement price of .001 (1/100th of a cent) per share, it would have only cost him about $2200. According to the recent 10-K for last year, he made over $234K. $2200 would only be less than 1% of that. The fact that he didn't purchase those shares shows that he has absolutely no confidence in the company at all.
Technically you are full of shit as usual. Next yes ge has to declare his shares being sold if he does. You tout the BS and then stand by it even knowing you are wrong.
Wow. I can tell I'm dealing with a truly superior intellect.
"so Rice did dump shares."..." we don't know if Rice is still holding his shares."..."He might have dumped them all"
he did dump shares...he might have dumped shares...then again he might be holding them all...
SMGDH and LOL
A cashless exercise by defintion means that shares were sold, so Rice did dump shares.
In addition, we don't know if Rice is still holding his shares. He might have dumped them all in the last few weeks or months.
No, dribble is correct. It seems fit for your childish reaction to my original simple comment.
Of all things to address, it’s childish to say something like.“how can you have such an opinion”
Ha yup dribble fits!! Also, GooGoo GaGa fits lol
Go back a read the thread…..SMH!!!
He's alot more right than you were when you said Rice was dumping shares. Remember that?
Hey gruber,
I'm with EOT on the "ruck" reference ... being a lad from down under ... a ruck is a rugby term -- a group of players around the ball on the ground ... they usually break from this formation when the "ball(s)" smell becomes too great ... LOL.
You can't seem to quite let it go, like you claimed you would.
And the term you're looking for is "drivel."
"Dribble" is what happens when you are sipping on your juice box and you spill a little bit, Dr. Comprehension.
Or is that another auto-correct?
<< We might already be past the tonnage mark and it's not announced. >>
WRONG AGAIN!
More pumping BS....
Strange to keep commenting on meaningless dribble. It’s Your bizarre reaction to my original statement why I didn’t bother observing the “auto correct” smh
I hope that's the case.
Yeah, that seems like a good idea.
Misspelling an insult based on implying someone's reading comprehension skills are poor isn't really a good look.
"Good ruck" to you, too.
Did you say "party"? I'm ready for that. When I read an article in a waiting room magazine about KBLB, I knew I would have to invest if I had any hope of retirement. 2016 bought my first shares and kept buying when I found some cash and unwanted shares. My retirement target is 5 years overdue but I bought a lot cheap shares (1.2M now) so I can wait another year or so. Especially if there's a millionaire party. Go KBLB.
We might already be past the tonnage mark and it's not announced. Look how much was on the table in February last year and not announced. Heck, when we have the KBLB millionaires party, we should all eat a worm.
I'm looking forward to that. I'm sure there are some great recipes.
Beyond Kong and Very Strong!
MCA
Thank you for that.
The crazy thing is this guy thinks he's smarter than AI. What's even crazier is him insulting me for using it even though in February I said my next 2 target dates are 2026 and 2029, without the use of AI.
Some people just LIVE to argue and do so with absolutely nothing of substance to say other than "you're wrong."
It's sad that these people get to vote in elections.
The silkworm to be eaten should be a BAM1 silkworm.
Only our resident "Karen's" would hold you to eating that silkworm, not most of us. Another week, another batch begins and one ends. They may well have more than a metric ton in totality, but the early goal per Ben is to get to metric ton per batch.
Only took them how many years to do what we said they should do! Is it a sign that they finally figured out what a gas pedal is so they can push the accelerator?
“1Q 2025. I was 100% sure they would hit it.”
Just because it wasn’t announced by April 1st. It Doesn’t take much calculation to figure out they have soared past that. Kraig has the healthiest biggest silkworms ever. With ZERO health issues!!
“Now I have to eat a friggin’ silkworm.”
Not even close
This is absolutely hilarious webby… can a guy make a fool out of himself anymore than that. How in the world did he honestly believe Thompson was going to meet his metric tonnage on 1 April? … has Thompson ever met any of the timelines he’s PR”d in the last 15 years…. You can guarantee you’re not gonna see any of that tonnage for the rest of the year… he’s going to smoke screen you with something else with the old PR distractions he pulls… I’ve never seen more people being played in my life. Honestly, this is absolutely hilarious to watch. Based on Thompson’s past history, anybody can predict the share price will be exactly what it is today. Come, December…. I can just hear banana boy right now…” oh hell no there’s going to be a buyout before that, load up people”… him, and Thompson are cut out the same mold… they very well may be the same person
<< I’ll do it when I am damn good and ready and can get to Michigan. >>
"I promise that I will eat a silkworm on YouTube if they don't meet metric tonnage by April 1, 2025. And I will do it in front of KBLB headquarters."
To some, the metric ton reveal means everything. In reality, though, the KBLB timing means more!
Only took them how many years to do what we said they should do! Is it a sign that they finally figured out what a gas pedal is so they can push the accelerator? Is it a sign that they have achieved metric tonnage?
I am annoyed they missed their target of metric tonnage by 4Q 2024 or 1Q 2025. I was 100% sure they would hit it. Now I have to eat a friggin’ silkworm. Wth.
I don’t live across the street from KBLB HQ and I don’t have a can of silkworm pupae to eat yet, plus, what consideration did you give up — zero. So don’t be pushy. I’ll do it when I am damn good and ready and can get to Michigan. With the announcement and launch of Spydasilk website maybe they have achieved a metric ton? So hold on to your saliva drool.
the form 4 came out over a week ago...the actual transactions occurred months ago...and the convertion of the warrrants took place at those prices listed in the form 4...but Rice paid .001 for those shares...and he paid that with some the shares he converted...thus he paid nothing out of pocket...
so no, that does not explain the volume or pps activity...
The fact that one exists is maybe notable...
There you go again, countering speculation, rumor, innuendo, and personal attacks with irrefutable logic.
You're never gonna win this argument.
It looks like Jon exercised some options before they expired and purchased some shares at slightly above market value. That might signal some confidence in a price rise. Or it might not. We may or may not find out...
The KBLB way.
That’s supposed to be comprehension issues.
I’ll just leave it at that from my original comment that you responded too. Good ruck lol
Followers
|
652
|
Posters
|
|
Posts (Today)
|
8
|
Posts (Total)
|
286565
|
Created
|
05/04/08
|
Type
|
Free
|
Moderators gimmegimmeminemine Money4Nothing-M4N WebSlinger |
Email: corporate@KraigLabs.com
KRAIG LABS WEBSITE FOR INVESTORS
Quarterly and Annual Reporting to the SEC is available on the Company's Website and EDGAR.
* Financial Statements * SEC Filings *
Outstanding Shares as of January 12, 2023
For issues or questions relating to share certificates or the transfer of securities please contact the company's transfer agent:
Olde Monmouth Stock Transfer Co., Inc.
200 Memorial Pkwy.
Atlantic Highlands, New Jersey 07716
Phone: (732) 872-2727
(since August 14, 2013)
Kraig Biocraft Laboratories, Inc. (KBLB) is the first company with a commercially feasible spidersilk to be mass produced.
Kraig Labs is a biotechnology company focused on the development of commercially significant high performance polymers and technical fibers. Kraig Lab's focus has been on the production of a transgenic silkworm incorporating specific gene sequences from the golden orb weaving spider. These specific gene sequences inserted are to enable the silkworm to spin a new recombinant fiber which incorporates spider silk proteins. With the scientific breakthrough announced on September 29, 2010, Kraig Labs is now working to commercialize the transgenic silkworms to compete in the garment industry silk market. The value for the chinese raw silk market alone is 3-5 billion per annum. With the creation of 20 seperate transgenic silkworms, all with unique properties, Kraig Labs is now working at an accelerated pace to build upon their first generation transgenic organisms to develop their second generation of transgenic silkworm incorporating spider silk proteins. The scientists nearly doubled the strength of the silkworm with these specific spider gene insertions. Their second generation of transgenics are expected to be complete in 2011. These second generation organisms are to be compared with the strength, flexibility and resiliency of the native spider in which the gene sequences are derived from. These fibers which will match the strength of spider silk are expected to compete in the technical textiles market valued in excess of 120 billion per annum. The 3rd generation organisms are currently in the planning phase. These organisms are expected to spin fibers exceeding the strength of native spiders and may incorporate gene sequences that release an antibiotic, or to help reduce scarring with use in bandages.
Kraig Biocraft Laboratories has a sponsored research and development program with the University of Notre Dame, and the University of Wyoming. The genetic work is occurring at the University of Notre Dame, headed by Dr Malcolm Fraser, Phd. The gene sequences are derived from Dr. Randy Lewis's(University of Wyoming) patented gene sequences of the golden orb weaving spider. Kraig labs is paying for all expenses incurred for this research and development program, and thus Kraig Labs has exclusive global commercialization rights with the technologies developed, including methods, organisms, and fibers produced.
MANAGEMENT
Kim Thompson, Founder and CEO
As the CEO of the company, Mr. Thompson is the only member of the scientific advisory board who is also
a part of the corporation's management. His formal education lies in the fields of economics and law.
He received his B.A. in Applied Economics from James Madison College at Michigan State University.
He received his Juris Doctorate from the University of Michigan Law School in 1994.
Mr. Thompson founded Kraig Biocraft Laboratories in his pursuit of the development of new biotechnologies
with industrial applications. As chairman of the scientific advisory board, he brings a unique perspective,and
acts as the primary liaison between the advisory board and the corporation.
Mr. Thompson brings a wealth of experience in business management and consultation to Kraig. Following
the completion of his undergraduate degree, Mr. Thompson joined California Craftsman, Inc. as a
Vice-President with primary responsibility for both marketing and human resources.
Kim Thompson was the director of business development at Franchise Venture Partners, LLC. He subsequently
joined the firm of Shearson, Lehman, Hutton where he specialized in equity trading and research of small cap
companies. Mr. Thompson received the highest series seven score for all Shearson brokers in his class nationwide.
His experience in those small cap equity markets has proven to be invaluable both in his legal and business successes.
Prior to becoming a public company CEO, Mr. Thompson was the founder and senior litigation partner in a California
commercial law firm where he worked as corporate and litigation counsel to privately held and public companies.
His many accomplishments in corporate law include winning and collecting in full what his firm believes to have been
the largest award of lost profits in a California commercial arbitration up to that time. An important part of his work was
winning victories on behalf of corporate clients in disputes over intellectual property and distribution rights. He has
represented business clients ranging from small start ups and micro caps to Fortune 100 companies.
With a background in business leadership and in advising public and private corporations, Kim Thompson continues
to bring a unique perspective to the successful management of business. His extensive business and legal background
enables him to create practical solutions to business problems and seize opportunities for growth.
Mr. Thompson is a member of the Triple Nine Society for persons with documented genius level IQs (having tested above
the 99.9th percentile). He is also active in the realm of science and invention where he has to his credit a number of
provisional patent applications including innovations in the areas of biotechnology, organic polymers, genetic engineering
and magnetic field manipulation, among others.
Mr. Rice has over 13 years’ experience growing development stage businesses with a focus on technology development, commercialization, and go to market strategies. Mr. Rice holds a B.S. in Chemical engineering from Michigan Technological University.
Prior to joining Kraig Biocraft Laboratories Mr. Rice was the Director of Advanced Technologies for Ultra Electronics, AMI. In this role, Mr. Rice was responsible for the identification, capture, and execution of new technology programs. During his tenure with AMI, Rice secured more than twenty five million dollars in funded development programs from the US Department of Defense which his team successfully leveraged into commercially viable spinoff products. Mr. Rice was also responsible for technical sales, marketing, and promotion of AMI’s products and capabilities. Rice joined AMI as the third full time employee and helped to lead the organization through its rapid growth and ultimate acquisition by Ultra Electronics in 2011.
Earlier in his career Mr. Rice developed unique advanced manufacturing techniques, established and trained a production staff, led engineering development, authored numerous technical papers, and is a recognized subject matter expert. Mr. Rice holds 5 issued patents and numerous provisional patents.
Mr. Rice brings a history of transforming revolutionary ideas into viable commercial products.
Mr. Rice is currently completing his Masters of Business Administration through the Executive Program at the Eli Broad College of Business: Michigan State University.
Despite the huge potential of genetically modified animals outside of laboratory research, commercialisation of these animals has been extremely limited. Numerous factors, including negative consumer perception, regulatory hurdles, and limitations inherent to classical GM technologies, have kept the majority of GM animal applications within the realm of academic research. However genome editing using zinc finger nucleases could help develop new markets for the future commercialisation of GM animals.
Genetic modification is commonplace throughout the life sciences sector, from fundamental research to pharmaceutical testing. GM cellular and animal models are valuable tools for the study of many chronic diseases, the testing of pharmaceutical compounds and the development of new therapeutic strategies. Genetic modification also offers great benefits in vaccine and biopharmaceutical manufacturing, which rely heavily on the use of GM organisms for biomolecule design and production. Modifying the genome of an organism or cell line allows the incorporation of target biomolecules in specific biological contexts, as well as the transfer of a gene product from a low-producing organism to one that can produce on a commercial scale. These applications have been widely accepted for many years, with countless GM organisms approved for medical manufacturing applications by drug regulators in all major countries. Despite this widespread success within the research and pharmaceutical sectors, the use of GM organisms outside of these markets has been limited.
Despite the lack of broad acceptance for most commercial applications of GM animal products, this technology has been able to gain traction in a few market sectors. The most obvious application has been the commercialisation of transgenic animals for the production of biomolecules for therapeutic use. Cattle, sheep and goats have been used for large-scale production of antibodies, steroids and hormones - most notably insulin - for many years. In 2009, GTC Biotherapeutics received US FDA approval for bioproduction of a recombinant human antithrombin. This product - ATryn - is extracted from the milk of transgenic goats, and is the first approved biopharmaceutical to be produced using genetically engineered animals. Although this is a significant breakthrough for the commercialisation of GM animals, it is still within the pharmaceutical industry, and is a natural progression of existing cell-based technologies. Of potentially greater commercial interest is the extension of genetic engineering outside of this sector, into areas such as food production, textiles and even companion animals.
GM crops have been available in many countries since the early 1990s, and numerous cash crops - including sugar beet, soybean, corn and tomatoes - have been modified to improve resistance to disease, increase the rate of growth or enhance nutritional value. However, cultivation of these transgenic crops is generally tightly regulated, particularly within the European Union, and this, together with negative public opinion, has limited the more widespread development of GM technologies.
Similar to GM crops, many of the animals currently under development are intended to confer disease resistance, an application particularly suited to the use of zinc finger nuclease (ZFN) technology. Many diseases can be treated by the targeted deletion or modification of a host gene. With ZFNs, these targets can be modified with no footprint of genetic engineering. Due to the high costs of raising livestock, another area of focus in developing commercial GM animals has been increasing the rate of growth or size of animals. Among the first GM animals likely to be launched is a fast growing salmon from AquaBounty. The AquAdvantage Salmon is designed to reach market size in half the time of a wild type salmon, reducing costs for fish farmers and limiting the environmental impact of salmon farming by avoiding the need for ocean pens.
Although genetic engineering of animals for food is primarily driven by economic pressures, GM technologies have also been used in the companion animals market. In this sector, genetic modification can be used for practical purposes - such as the creation of hypoallergenic animals or the correction of heritable congenital defects which have arisen though inbreeding - or for purely cosmetic purposes, such as GloFish. The first example of a GM pet, GloFish are fluorescent zebrafish (Danio rerio) that have had genes encoding naturally fluorescent proteins (GFP, YFP, RFP) inserted into their genome. Developed by a group at the National University of Singapore, GloFish were originally created to develop live detection systems for water pollution. They were introduced as pets in the United States in 2003 following over two years of extensive environmental research and consultation. In Europe however, the sale and possession of GloFish is prohibited by rigorous legislation concerning the use of GM technologies.
By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels
Perhaps even more interesting from a commercial perspective is the use of GM animals in the manufacture of textiles. Silkworms - actually the larval form of the silkmoth Bombyx mori - have been used for the production of silk for thousands of years, with natural silk still produced by the cultivation of silkworms today. Silkworm cocoons are unwound to create linear silk threads, then re-spun into textiles in much the same way as cotton. Although the applications of silkworm silk are numerous, due to their unique physical and chemical properties, there is also widespread interest in the silks of several other insects.
Spider silk, in particular, offers numerous possibilities within the technical textiles industry, due to its incredible tensile strength and elasticity; characteristics which have not yet been replicated in synthetic materials. Like all insect silks, spider silk fibres consist of repetitive units of protein crystals separated by less structured protein chains. The exact properties and composition of each spider silk vary with its intended function. Major Ampullate or dragline silk, for example, is relatively hydrophobic with very high tensile strength and toughness, as it is used to form the outer rim and spokes of a web. In contrast, hydrophilic capture spiral silks, which form the inner structures of the web, are sticky and highly elastic to effectively entrap prey. This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics, for applications such as bulletproof vests, parachute canopies and automobile airbags; biomedical applications, including sutures and tendon and ligament repair; new fabrics, for sportswear and clothing; and even microelectronics.
Although the use of spider silks for microsutures has recently been reported, more widespread application of spider silk technologies is currently limited by the difficulty in producing silks on a commercially viable scale. This is due to the difficulties of rearing spiders in large numbers, due to their highly territorial and cannibalistic nature. As a result, the harvesting of spider silk fibres is extremely time consuming and labour intensive, with production of the only known spider silk garment - an 11 foot by 4 foot shawl made from golden orb spider silk - taking 150 people over five years to produce and costing in excess of £300,000!
.
To overcome these limitations, and allow future development of spider silk technologies, an alternative strategy for spider silk production is required. This makes spider silk production an obvious candidate for genetic modification, inserting spider silk genes into the genome
of other silk-making insects for bioproduction. For example, random insertion of orb spider silk genes into silkworms has allowed production of hybrid spider/silkworm silk using traditional silkworm farming strategies. The resulting hybrid silk contains approximately 10% spider silk
and has greater strength and durability than native silkworm silk, raising the possibility of using transgenic silkworms to produce pure spider silks.
Though straightforward in principle, the exchange of native silkworm genes for spider silk genes, alongside more widespread exploitation of genetic engineering, has been limited by the inherent restrictions of conventional GM technologies.
The generalised process of modifying an organism requires several capabilities, including:
While many different techniques exist for accomplishing each of these steps, most GM technologies offer a compromise between the efficiency of the technique and the ability to accurately and precisely target the locus of interest. Viral genomic delivery technologies effectively deliver nucleic acids to cells and organisms, but fall short on ability to target specific regions of the genome, generally only allowing random insertion of genetic material. In comparison, transposase technologies allow a greater degree of targeting, but leave unwanted traces of exogenous DNA in their wake. Other methods involve the introduction of naked DNA into the cell, which results in insertion into the genome at very low frequencies, usually at random, limiting this approach to organisms that can be economically cultivated at high densities and screened in large numbers. Simply put, most techniques for genetic manipulation are random, inefficient and leave a 'footprint' of foreign DNA. While this is usually tolerated in basic research, it is not acceptable for most commercial applications, and has been a major hurdle for GM animal technologies to date.
The advent of zinc finger nuclease (ZFN) technology represents a significant breakthrough for commercialisation of GM animal products, offering precisely targeted, efficient genome editing for the first time. Commercially available through Sigma Life Science under the CompoZr brand, this technique can be used to create permanent and heritable changes to an organism of interest.
This high degree of variability offers enormous potential for the textiles industry, raising the possibility of tailoring the properties of silk to create advanced technical fabrics
ZFNs are a class of engineered DNA binding proteins that facilitate targeted editing of the genome by creating double-strand breaks at user-specified locations. These breaks stimulate the cell's natural DNA repair mechanisms - homologous recombination (HR) and non-homologous end joining (NHEJ) - which can be exploited to achieve rapid and permanent site-specific modification of the desired genes. While HR can be used to insert foreign DNA sequences, NHEJ allows the cell's natural processes to create precisely targeted mimics of natural mutations which leave no traces of foreign DNA. Unlike previous techniques, ZFNs offer excellent sequence specificity, binding 24 to 36 base pair target sequences to virtually eliminate off target effects, and are able to achieve modification rates exceeding 20 %, well above rates for most other technologies.
The technique is already being used to create transgenic silkworms for spider silk production. By allowing precisely targeted insertion of spider genes and concomitant removal of endogenous silkworm silk genes at the same locus, ZFN technology offers the potential for development of transgenic silkworms which will produce native spider silk at commercially viable levels.
GM technologies have revolutionised the research world and have great potential in a variety of commercial applications, but have been limited by the inherent restrictions associated with historical GM technologies. The main drawback of these technologies is their inability to accurately and efficiently target genes of interest, instead relying on random insertion of genetic material into host genomes. These limitations result in the need for extensive and costly screening to identify animals with correct transgene expression (without compromising the viability of the animal), and also result in the co-expression of both the transgene and native homologues already present.
The advent of ZFN technology signifies the beginning of an exciting new chapter in the world of genetic modification, allowing precise, targeted and efficient genome editing for the first time. Production of native spider silk using transgenic silkworms is just one example of the potential commercial applications of this innovative technology, taking us one step closer to the reality of industrial scale biomanufacturing and paving the way for an entirely new spectrum of environmentally friendly materials.
Authors:
Joseph Bedell and Brian Buntaine
Commercial Animal Technologies Group, Sigma Advanced Genetic Engineering (SAGE) Labs, Sigma Life Science
HEADLINES FOR KRAIG BIOCRAFT LABORATORIES / (KBLB):
PHOTOS FROM VIETNAM POSTED JULY 6, 2018
ANN ARBOR, Mich., – January 7, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has successfully delivered the first two shipments of its highly specialized silkworms, which produce a silk with the physical characteristics of spider silk, to Vietnam.
Today’s announcement is the culmination of more than 5 years of work, and challenging negotiation, with the government of Vietnam. The silkworms from these first two shipments have already hatched and are now enjoying a fresh mulberry diet, so, for the first time in history, the global demand for spider silk materials has a viable, cost effective, and scalable solution.
“The dream of commercializing our powerful technology is now materializing. This marks a dramatic leap forward in Kraig Labs’ business plan for commercial production and mass marketing of cost effective recombinant spider silk, and becomes the foundation for an entirely new industry,” said, COO, Jon Rice. “To our long-term shareholders, who have taken this journey with us, as well as our team in the US and Vietnam, who have worked tirelessly to make this dream a reality, I cannot thank you enough. As we start the New Year, full of new opportunity, we truly have something incredible to celebrate.”
The Company has been working with leading sericulture experts, biotechnology institutions, and governmental agencies, in Vietnam, to further boost the silk industry with our revolutionary technology. Kraig Labs is currently finalizing renovation plans for a ~46,000 square foot production factory in Quang Nam Province, Vietnam.
“Our plan has always been to bring our technology to the silk producing regions of the world for rapid scale-up,” said, CEO and Founder, Kim Thompson. “Today we see the fruits of that effort. With its massive silk infrastructure and production capacity, Vietnam is an ideal location to launch our technology scale-up. Congratulations to our team and shareholders, as we prepare for the realization of large scale production.”
\
\
Volume: | 710,105 |
Day Range: | 0.0825 - 0.09 |
Last Trade Time: | 12:46:33 PM EDT |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |